TB-500 Evidence: Thymosin Beta-4 Mechanisms and Data

Clinical Question

Does the evidence for TB-500 support its systemic use for tissue repair, and what are the specific mechanisms identified in clinical research to date?

Evidence Snapshot

Compound: TB-500 (43-amino acid actin-sequestering peptide, synthetic Thymosin Beta-4).
Evidence Grade: C+
Study Types: Phase II clinical trials (topical applications only).
Regulatory Status: Not FDA approved; Category 2 (September 2023); 503b Not listed.
Outcomes: Evidence of cell migration and proliferation in topical wound healing; lack of human data for systemic administration.

What the Research Shows

TB-500, a synthetic version of the 43-amino acid peptide Thymosin Beta-4, has been investigated primarily for its role in cellular repair and motility. The research indicates that the peptide promotes cell migration, proliferation, and differentiation. Clinical evidence is currently concentrated in Phase II trials conducted by the RegeneRx clinical program, which focused on topical delivery methods, including corneal drops and wound dressings. These trials demonstrated the peptide's utility in localized wound healing environments.

However, there is a significant discrepancy between clinical data and common application methods. While TB-500 is frequently discussed in the context of systemic injection, the available human data is limited to these topical applications. Furthermore, the RegeneRx clinical program has been described as stalled or abandoned, leaving a gap in the progression toward late-stage human trials.

Mechanism

The mechanism of TB-500 centers on its role as an actin-sequestering peptide. It specifically binds to G-actin monomers, which facilitates the upregulation of actin expression and enhances cell motility. At injury sites, the peptide is shown to reduce inflammation and promote angiogenesis (the formation of new blood vessels). Additionally, the peptide activates satellite cells, which are essential for muscle repair processes. By promoting these specific cellular behaviors, the peptide supports the migration of cells to areas of tissue damage.

Limitations of the Evidence

The primary limitation of the current evidence base is the lack of human data regarding systemic administration. Although Phase II trials were conducted, they utilized topical delivery systems (dressings and drops) rather than the systemic injections often associated with the compound in non-clinical discussions.

Regulatory oversight has highlighted further concerns. The FDA has cited an immunogenicity risk associated with the compound, noting a lack of human exposure data to support its safety profile. In September 2023, it was classified as Category 2. Additionally, regulatory history includes a 2020 warning letter issued to Tailor Made regarding the compound. The shortage status is currently listed as "No" as of March 2026.

Clinical Takeaway

TB-500 demonstrates a clear mechanism for enhancing cell motility and angiogenesis through G-actin binding, with Phase II data supporting its use in topical wound healing. However, clinicians should note that systemic human data is absent, and the FDA has identified potential immunogenicity risks. The abandonment of formal clinical programs further limits the availability of high-grade evidence for broader clinical applications.

Sources

TruthTides Peptide Database: TB-500 Clinical Profile (Grade C+).
Regulatory Status Record: ID c8181049-d986-4a2f-8b55-2bf1e9eacaea (March 2026).
FDA Warning Letter (2020) and Category 2 Listing (Sept 2023).

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

Physicians seeking to understand how these findings translate to a clinical environment may consult with a peptide therapy clinic to review current regulatory standings. For assistance in locating a qualified professional, you may find a doctor through our verified provider directory. The cost of such consultations and any subsequent protocols varies by prescriber and location.